Skip to content
View original post on X: Fidji Simo· 20/100AI score20/100

Fidji Simo welcomes ChronicleBio AI, backed by Morgan Cheatham and Jimi Hendrix

AISummary

Fidji Simo says she is excited to work with Morgan Cheatham and Jimi Hendrix, two early investors who recognized the importance of data in AI biotech.

Morgan Cheatham's linked post says the partnership supports ChronicleBio, which is building AI models to identify biologically distinct patient subgroups within complex chronic diseases.

The team reportedly combines clinical phenotyping, molecular measurement, and AI, and its early work has surfaced disease subtypes linked to potentially relevant therapies.

Post on XView on X
@fidjissimo

Very excited to work with @morgancheatham @jimihendrixlive on this; they were one of the first investors to bet on the importance of data in AI bio and to really get how the next biotech companies will be built.

Morgan Cheatham, MD@morgancheatham
we are beyond excited to partner with @fidjissimo and the @ChronicleBioAI team as they build a new model for understanding and treating complex, chronic disease. biological heterogeneity hidden within common chronic conditions is one of the grand challenges in medicine. Many conditions remain syndromic rather than mechanistically resolved. patients may share a diagnosis while harboring meaningfully different underlying biology, often without validated biomarkers to distinguish those states. that ambiguity complicates diagnosis, therapeutic selection, and clinical development. the best undiagnosed disease programs solve a version of this problem through deep synthesis across phenotype, molecular data, and clinical expertise. ChronicleBio is bringing a similar level of synthesis to a much broader population and to diseases that affect millions of people. by integrating deep clinical phenotyping, advanced molecular measurement, and AI, the team is working to identify biologically coherent patient subgroups and construct a more granular map of disease. their early work has already surfaced distinct subtypes across complex chronic illness and begun linking those subtypes to potentially relevant therapies. huge thanks to @Forbes for sharing the story. @jimihendrixlive
View quoted post on X

Source: Fidji Simo · x.comPublished · added here